Spring Bank Pharmaceuticals CEO and leadership

Martin Driscoll is a Chairman, President and Chief Executive Officer at Spring Bank Pharmaceuticals Inc and is based in Hopkinton, Massachusetts.

Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of OrigenixTechnologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumentalin advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of theDiscovery Group at Hybridon, Inc. (now IderaPharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and ResearchatFDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the OakRidge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications. In 2004, Kris was elected as a Fellow of Royal Society of Chemistry, UK and in 2008 he was elected as a Fellow of International Society of Physical Sciences. In 2004, he was awarded the M. L. Khorana Memorial Award by the Indian Pharmaceutical Association and in 2003 elected as the UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences. Kris has served on the Scientific Advisory Board of TopigenPharmaceuticals, Inc. and currently serves on the National Institutes of Health (NIH) review panel for grants and contracts.

Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of OrigenixTechnologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumentalin advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of theDiscovery Group at Hybridon, Inc. (now IderaPharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and ResearchatFDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the OakRidge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications. In 2004, Kris was elected as a Fellow of Royal Society of Chemistry, UK and in 2008 he was elected as a Fellow of International Society of Physical Sciences. In 2004, he was awarded the M. L. Khorana Memorial Award by the Indian Pharmaceutical Association and in 2003 elected as the UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences. Kris has served on the Scientific Advisory Board of TopigenPharmaceuticals, Inc. and currently serves on the National Institutes of Health (NIH) review panel for grants and contracts.

Martin Driscoll is a Chairman, President and Chief Executive Officer at Spring Bank Pharmaceuticals Inc and is based in Hopkinton, Massachusetts.

Kris is an innovator in the fields of nucleic acid chemistry, bioorganic chemistry and pharmaceutical sciences. He was co-founder and VP of Discovery of OrigenixTechnologies, Inc. from 1998 to 2002. There he directed a team of 30 scientists in chemistry and biology and was instrumentalin advancing several programs from discovery to clinical development. From 1993 to 1998, Kris was a Senior Scientist and Associate Director of theDiscovery Group at Hybridon, Inc. (now IderaPharmaceuticals, Inc.). Previously, Kris was a Professor of Medicinal Chemistry at the University of Bombay, a Visiting Scientist at the University of Texas, M.D. Anderson Cancer Center and a Visiting Scientist at the Center for Biologics Evaluation and ResearchatFDA/NIH. Kris received his BS (Hons) in chemistry, BS and MS degrees in Medicinal and Pharmaceutical Chemistry from the University of Bombay. He received his PhD degree in Pharmaceutical Sciences from the University of the Pacific, Stockton, California and carried out postdoctoral work at the OakRidge National Laboratory and at the Johns Hopkins University. He is an author of over 100 scientific papers and several books on organic synthesis and is an inventor of more than 100 patents and patent applications. In 2004, Kris was elected as a Fellow of Royal Society of Chemistry, UK and in 2008 he was elected as a Fellow of International Society of Physical Sciences. In 2004, he was awarded the M. L. Khorana Memorial Award by the Indian Pharmaceutical Association and in 2003 elected as the UICT Diamond Jubilee Distinguished Fellow in Pharmaceutical Sciences. Kris has served on the Scientific Advisory Board of TopigenPharmaceuticals, Inc. and currently serves on the National Institutes of Health (NIH) review panel for grants and contracts.